Abstract
Serine proteases have been implicated in many stages of cancer development, facilitating tumor cell growth, invasion, and metastasis, and naturally occurring serine protease inhibitors have shown promise as potential anticancer therapeutics. Optimal design of inhibitors as potential therapeutics requires the identification of the specific serine proteases involved in disease progression and the functional targets responsible for the tumor-promoting properties. Here, we use the HMT-3522 breast cancer progression series grown in 3D organotypic culture conditions to find that serine protease inhibitors cause morphological reversion of the malignant T4-2 cells, assessed by inhibition of proliferation and formation of acinar structures with polarization of basal markers, implicating serine protease activity in their malignant growth behavior. We identify PRSS3/mesotrypsin upregulation in T4-2 cells as compared to their nonmalignant progenitors, and show that knockdown of PRSS3 attenuates, and treatment with recombinant purified mesotrypsin enhances, the malignant growth phenotype. Using proteomic methods, we identify CD109 as the functional proteolytic target of mesotrypsin. Our study identifies a new mediator and effector of breast cancer growth and progression.
Similar content being viewed by others
References
Rawlings ND, Morton FR, Barrett AJ (2006) MEROPS: the peptidase database. Nucleic Acids Res 34:D270–D272
Borgono CA, Diamandis EP (2004) The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 4:876–890
Duffy MJ (2004) The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des 10:39–49
Netzel-Arnett S, Hooper JD, Szabo R, Madison EL, Quigley JP, Bugge TH, Antalis TM (2003) Membrane anchored serine proteases: a rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer. Cancer Metastasis Rev 22:237–258
Nyberg P, Ylipalosaari M, Sorsa T, Salo T (2006) Trypsins and their role in carcinoma growth. Exp Cell Res 312:1219–1228
Sun Z, Yang P (2004) Role of imbalance between neutrophil elastase and alpha 1-antitrypsin in cancer development and progression. Lancet Oncol 5:182–190
Bhatt AS, Welm A, Farady CJ, Vasquez M, Wilson K, Craik CS (2007) Coordinate expression and functional profiling identify an extracellular proteolytic signaling pathway. Proc Natl Acad Sci USA 104:5771–5776
Hansen KK, Oikonomopoulou K, Baruch A, Ramachandran R, Beck P, Diamandis EP, Hollenberg MD (2008) Proteinases as hormones: targets and mechanisms for proteolytic signaling. Biol Chem 389:971–982
Wilson TJ, Nannuru KC, Futakuchi M, Sadanandam A, Singh RK (2008) Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-kappaB ligand. Cancer Res 68:5803–5811
Ruf W, Mueller BM (2006) Thrombin generation and the pathogenesis of cancer. Semin Thromb Hemost 32(Suppl 1):61–68
Armstrong WB, Kennedy AR, Wan XS, Taylor TH, Nguyen QA, Jensen J, Thompson W, Lagerberg W, Meyskens FL Jr (2000) Clinical modulation of oral leukoplakia and protease activity by Bowman–Birk inhibitor concentrate in a phase IIa chemoprevention trial. Clin Cancer Res 6:4684–4691
Kennedy AR (1998) Chemopreventive agents: protease inhibitors. Pharmacol Ther 78:167–209
Kobayashi H, Yagyu T, Inagaki K, Kondo T, Suzuki M, Kanayama N, Terao T (2004) Therapeutic efficacy of once-daily oral administration of a Kunitz-type protease inhibitor, bikunin, in a mouse model and in human cancer. Cancer 100:869–877
Kobayashi H, Suzuki M, Hirashima Y, Terao T (2003) The protease inhibitor bikunin, a novel anti-metastatic agent. Biol Chem 384:749–754
Malkowicz SB, McKenna WG, Vaughn DJ, Wan XS, Propert KJ, Rockwell K, Marks SH, Wein AJ, Kennedy AR (2001) Effects of Bowman–Birk inhibitor concentrate (BBIC) in patients with benign prostatic hyperplasia. Prostate 48:16–28
Putnam JB, Royston D, Chambers AF, Dunbar S, Lemmer JH, Norman P, Travis E, Vaporciyan AA, Yang S, Zacharski LR (2003) Evaluating the role of serine protease inhibition in the management of tumor micrometastases. Oncology (Williston Park) 17:9–30 quiz 31-32
Nguyen HH, Aronchik I, Brar GA, Nguyen DH, Bjeldanes LF, Firestone GL (2008) The dietary phytochemical indole-3-carbinol is a natural elastase enzymatic inhibitor that disrupts cyclin E protein processing. Proc Natl Acad Sci USA 105:19750–19755
Lippman SM, Matrisian LM (2000) Protease inhibitors in oral carcinogenesis and chemoprevention. Clin Cancer Res 6:4599–4603
Cuzick J (2003) Treatment of DCIS—results from clinical trials. Surg Oncol 12:213–219
Senn HJ, Morant R (2008) Chemoprevention of breast and prostate cancers: where do we stand? Ann Oncol 19(Suppl 7):vii234–vii237
Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353:1784–1792
Jatoi I, Chen BE, Anderson WF, Rosenberg PS (2007) Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis. J Clin Oncol 25:1683–1690
Bissell MJ, Radisky D (2001) Putting tumours in context. Nat Rev Cancer 1:46–54
Bissell MJ, Radisky DC, Rizki A, Weaver VM, Petersen OW (2002) The organizing principle: microenvironmental influences in the normal and malignant breast. Differentiation 70:537–546
Wang F, Hansen RK, Radisky D, Yoneda T, Barcellos-Hoff MH, Petersen OW, Turley EA, Bissell MJ (2002) Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts. J Natl Cancer Inst 94:1494–1503
Weaver VM, Petersen OW, Wang F, Larabell CA, Briand P, Damsky C, Bissell MJ (1997) Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol 137:231–245
Park CC, Zhang H, Pallavicini M, Gray JW, Baehner F, Park CJ, Bissell MJ (2006) Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Res 66:1526–1535
Wang F, Weaver VM, Petersen OW, Larabell CA, Dedhar S, Briand P, Lupu R, Bissell MJ (1998) Reciprocal interactions between beta1-integrin and epidermal growth factor receptor in three-dimensional basement membrane breast cultures: a different perspective in epithelial biology. Proc Natl Acad Sci USA 95:14821–14826
Lee GY, Kenny PA, Lee EH, Bissell MJ (2007) Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Methods 4:359–365
Salameh MA, Soares AS, Hockla A, Radisky ES (2008) Structural basis for accelerated cleavage of bovine pancreatic trypsin inhibitor (BPTI) by human mesotrypsin. J Biol Chem 283:4115–4123
Szmola R, Kukor Z, Sahin-Toth M (2003) Human mesotrypsin is a unique digestive protease specialized for the degradation of trypsin inhibitors. J Biol Chem 278:48580–48589
Chase T Jr, Shaw E (1967) p-Nitrophenyl-p′-guanidinobenzoate HCl: a new active site titrant for trypsin. Biochem Biophys Res Commun 29:508–514
Dachsel JC, Taylor JP, Mok SS, Ross OA, Hinkle KM, Bailey RM, Hines JH, Szutu J, Madden B, Petrucelli L et al (2007) Identification of potential protein interactors of Lrrk2. Parkinsonism Relat Disord 13:382–385
Jessani N, Humphrey M, McDonald WH, Niessen S, Masuda K, Gangadharan B, Yates JR III, Mueller BM, Cravatt BF (2004) Carcinoma and stromal enzyme activity profiles associated with breast tumor growth in vivo. Proc Natl Acad Sci USA 101:13756–13761
Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161–174
Debnath J, Brugge JS (2005) Modelling glandular epithelial cancers in three-dimensional cultures. Nat Rev Cancer 5:675–688
Schmeichel KL, Bissell MJ (2003) Modeling tissue-specific signaling and organ function in three dimensions. J Cell Sci 116:2377–2388
Shaw KR, Wrobel CN, Brugge JS (2004) Use of three-dimensional basement membrane cultures to model oncogene-induced changes in mammary epithelial morphogenesis. J Mammary Gland Biol Neoplasia 9:297–310
Kenny PA, Bissell MJ (2003) Tumor reversion: correction of malignant behavior by microenvironmental cues. Int J Cancer 107:688–695
Liu H, Radisky DC, Wang F, Bissell MJ (2004) Polarity and proliferation are controlled by distinct signaling pathways downstream of PI3-kinase in breast epithelial tumor cells. J Cell Biol 164:603–612
Muschler J, Levy D, Boudreau R, Henry M, Campbell K, Bissell MJ (2002) A role for dystroglycan in epithelial polarization: loss of function in breast tumor cells. Cancer Res 62:7102–7109
Chen HM, Schmeichel KL, Mian IS, Lelievre S, Petersen OW, Bissell MJ (2000) AZU-1: a candidate breast tumor suppressor and biomarker for tumor progression. Mol Biol Cell 11:1357–1367
Diederichs S, Bulk E, Steffen B, Ji P, Tickenbrock L, Lang K, Zanker KS, Metzger R, Schneider PM, Gerke V et al (2004) S100 family members and trypsinogens are predictors of distant metastasis and survival in early-stage non-small cell lung cancer. Cancer Res 64:5564–5569
Han B, Nakamura M, Mori I, Nakamura Y, Kakudo K (2005) Urokinase-type plasminogen activator system and breast cancer (review). Oncol Rep 14:105–112
Kang JY, Dolled-Filhart M, Ocal IT, Singh B, Lin CY, Dickson RB, Rimm DL, Camp RL (2003) Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res 63:1101–1105
Parr C, Watkins G, Mansel RE, Jiang WG (2004) The hepatocyte growth factor regulatory factors in human breast cancer. Clin Cancer Res 10:202–211
Overall CM, Tam EM, Kappelhoff R, Connor A, Ewart T, Morrison CJ, Puente X, Lopez-Otin C, Seth A (2004) Protease degradomics: mass spectrometry discovery of protease substrates and the CLIP-CHIP, a dedicated DNA microarray of all human proteases and inhibitors. Biol Chem 385:493–504
Kenny PA, Lee GY, Myers CA, Neve RM, Semeiks JR, Spellman PT, Lorenz K, Lee EH, Barcellos-Hoff MH, Petersen OW et al (2007) The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol 1:84–96
Katona G, Berglund GI, Hajdu J, Graf L, Szilagyi L (2002) Crystal structure reveals basis for the inhibitor resistance of human brain trypsin. J Mol Biol 315:1209–1218
Cottrell GS, Amadesi S, Grady EF, Bunnett NW (2004) Trypsin IV, a novel agonist of protease-activated receptors 2 and 4. J Biol Chem 279:13532–13539
Dozmorov MG, Hurst RE, Culkin DJ, Kropp BP, Frank MB, Osban J, Penning TM, Lin HK (2009) Unique patterns of molecular profiling between human prostate cancer LNCaP and PC-3 cells. Prostate 69:1077–1090
Yang L, Zhang L, Wu Q, Boyd DD (2008) Unbiased screening for transcriptional targets of ZKSCAN3 identifies integrin beta 4 and vascular endothelial growth factor as downstream targets. J Biol Chem 283:35295–35304
Takeuchi T, Shuman MA, Craik CS (1999) Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. Proc Natl Acad Sci USA 96:11054–11061
Yamashita K, Mimori K, Inoue H, Mori M, Sidransky D (2003) A tumor-suppressive role for trypsin in human cancer progression. Cancer Res 63:6575–6578
Marsit CJ, Okpukpara C, Danaee H, Kelsey KT (2005) Epigenetic silencing of the PRSS3 putative tumor suppressor gene in non-small cell lung cancer. Mol Carcinog 44:146–150
Marsit CJ, Karagas MR, Danaee H, Liu M, Andrew A, Schned A, Nelson HH, Kelsey KT (2006) Carcinogen exposure and gene promoter hypermethylation in bladder cancer. Carcinogenesis 27:112–116
Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F, Salomon DS (2006) Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366:2–16
Flynn JF, Wong C, Wu JM (2009) Anti-EGFR therapy: mechanism and advances in clinical efficacy in breast cancer. J Oncol 2009:526963
Desgrosellier JS, Barnes LA, Shields DJ, Huang M, Lau SK, Prevost N, Tarin D, Shattil SJ, Cheresh DA (2009) An integrin alpha(v)beta(3)-c-Src oncogenic unit promotes anchorage-independence and tumor progression. Nat Med 15:1163–1169
Zhao Y, Bachelier R, Treilleux I, Pujuguet P, Peyruchaud O, Baron R, Clement-Lacroix P, Clezardin P (2007) Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases. Cancer Res 67:5821–5830
Pestov DG, Grzeszkiewicz TM, Lau LF (1998) Isolation of growth suppressors from a cDNA expression library. Oncogene 17:3187–3197
Killian A, Sarafan-Vasseur N, Sesboue R, Le Pessot F, Blanchard F, Lamy A, Laurent M, Flaman JM, Frebourg T (2006) Contribution of the BOP1 gene, located on 8q24, to colorectal tumorigenesis. Genes Chromosomes Cancer 45:874–881
Bach JP, Rinn B, Meyer B, Dodel R, Bacher M (2008) Role of MIF in inflammation and tumorigenesis. Oncology 75:127–133
Meyer-Siegler KL, Iczkowski KA, Leng L, Bucala R, Vera PL (2006) Inhibition of macrophage migration inhibitory factor or its receptor (CD74) attenuates growth and invasion of DU-145 prostate cancer cells. J Immunol 177:8730–8739
Verjans E, Noetzel E, Bektas N, Schutz AK, Lue H, Lennartz B, Hartmann A, Dahl E, Bernhagen J (2009) Dual role of macrophage migration inhibitory factor (MIF) in human breast cancer. BMC Cancer 9:230
Jiang X, Guo YL, Bromberg ME (2006) Formation of tissue factor-factor VIIa-factor Xa complex prevents apoptosis in human breast cancer cells. Thromb Haemost 96:196–201
Jiang X, Zhu S, Panetti TS, Bromberg ME (2008) Formation of tissue factor-factor VIIa-factor Xa complex induces activation of the mTOR pathway which regulates migration of human breast cancer cells. Thromb Haemost 100:127–133
Versteeg HH, Schaffner F, Kerver M, Ellies LG, Andrade-Gordon P, Mueller BM, Ruf W (2008) Protease-activated receptor (PAR) 2, but not PAR1, signaling promotes the development of mammary adenocarcinoma in polyoma middle T mice. Cancer Res 68:7219–7227
Arora P, Cuevas BD, Russo A, Johnson GL, Trejo J (2008) Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasion. Oncogene 27:4434–4445
Grishina Z, Ostrowska E, Halangk W, Sahin-Toth M, Reiser G (2005) Activity of recombinant trypsin isoforms on human proteinase-activated receptors (PAR): mesotrypsin cannot activate epithelial PAR-1, -2, but weakly activates brain PAR-1. Br J Pharmacol 146:990–999
Hashimoto M, Ichihara M, Watanabe T, Kawai K, Koshikawa K, Yuasa N, Takahashi T, Yatabe Y, Murakumo Y, Zhang JM et al (2004) Expression of CD109 in human cancer. Oncogene 23:3716–3720
Sato T, Murakumo Y, Hagiwara S, Jijiwa M, Suzuki C, Yatabe Y, Takahashi M (2007) High-level expression of CD109 is frequently detected in lung squamous cell carcinomas. Pathol Int 57:719–724
Zhang JM, Hashimoto M, Kawai K, Murakumo Y, Sato T, Ichihara M, Nakamura S, Takahashi M (2005) CD109 expression in squamous cell carcinoma of the uterine cervix. Pathol Int 55:165–169
Hasegawa M, Moritani S, Murakumo Y, Sato T, Hagiwara S, Suzuki C, Mii S, Jijiwa M, Enomoto A, Asai N et al (2008) CD109 expression in basal-like breast carcinoma. Pathol Int 58:288–294
Lin M, Sutherland DR, Horsfall W, Totty N, Yeo E, Nayar R, Wu XF, Schuh AC (2002) Cell surface antigen CD109 is a novel member of the alpha(2) macroglobulin/C3, C4, C5 family of thioester-containing proteins. Blood 99:1683–1691
Solomon KR, Sharma P, Chan M, Morrison PT, Finberg RW (2004) CD109 represents a novel branch of the alpha2-macroglobulin/complement gene family. Gene 327:171–183
Coussens LM, Fingleton B, Matrisian LM (2002) Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295:2387–2392
Fingleton B (2008) MMPs as therapeutic targets—still a viable option? Semin Cell Dev Biol 19:61–68
Sparano JA, Bernardo P, Stephenson P, Gradishar WJ, Ingle JN, Zucker S, Davidson NE (2004) Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. J Clin Oncol 22:4683–4690
Miller KD, Gradishar W, Schuchter L, Sparano JA, Cobleigh M, Robert N, Rasmussen H, Sledge GW (2002) A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancer. Ann Oncol 13:1220–1224
Miller KD, Saphner TJ, Waterhouse DM, Chen TT, Rush-Taylor A, Sparano JA, Wolff AC, Cobleigh MA, Galbraith S, Sledge GW (2004) A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancer. Clin Cancer Res 10:1971–1975
Acknowledgments
This work was supported by United States Department of Defense Breast Cancer Research Program concept grant W81XWH-06-1-0605 (ESR), Florida Department of Health Bankhead-Coley New Investigator Research Grant 07BN-07 (ESR), and the National Cancer Institute CA122086 (DCR)
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Supplemental Fig. 1
Transcriptional upregulation of selected serine proteases in T4-2 cells as compared with S1 cells. Quantitative PCR was used to assess transcript levels of mesotrypsin, prostatin, TMPRSS3, neurotrypsin, and matriptase-1 in cDNA isolated from S1 and T4-2 cells grown in 3D. Data are expressed as mean ± SD. P < 0.05 (unpaired t test) for all comparisons. (PDF 29 kb)
Rights and permissions
About this article
Cite this article
Hockla, A., Radisky, D.C. & Radisky, E.S. Mesotrypsin promotes malignant growth of breast cancer cells through shedding of CD109. Breast Cancer Res Treat 124, 27–38 (2010). https://doi.org/10.1007/s10549-009-0699-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-009-0699-0